BlinkLab Selected for Nationwide Autism Screening Program in Morocco
BlinkLab Limited (ASX: BB1) has been chosen to support Morocco’s national autism screening initiative, marking a significant milestone in the large-scale deployment of its Dx1 diagnostic technology. The program, led by the Moroccan government, will introduce early autism screening across the country, targeting children from as young as 18 months of age. This initiative is designed to enhance early detection and intervention capabilities, addressing a substantial public health need in a country with approximately 600,000 annual births and a significant number of individuals affected by autism. The rollout will be fully funded by government bodies, including the Foundation Mohammed V for Solidarity, removing financial barriers to implementation. BlinkLab will retain ownership of the data generated through the program, which is expected to provide valuable real-world insights into largescale screening applications. The initiative also aligns with internationally recognised healthcare standards, supporting equitable access to early diagnosis across regions. In addition, the program will include the development of a dedicated Center of Excellence for Autism Research, Education and Training, with participation from BlinkLab leadership. This deployment represents a major step in validating BlinkLab’s technology at scale, while positioning the company for potential future regulatory and commercial expansion.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
BlinkLab Selected for Nationwide Autism Screening Program in Morocco
BlinkLab Limited (ASX: BB1) has been chosen to support Morocco’s national autism screening initiative, marking a significant milestone in the large-scale deployment of its Dx1 diagnostic technology. The program, led by the Moroccan government, will introduce early autism screening across the country, targeting children from as young as 18 months of age. This initiative is designed to enhance early detection and intervention capabilities, addressing a substantial public health need in a country with approximately 600,000 annual births and a significant number of individuals affected by autism. The rollout will be fully funded by government bodies, including the Foundation Mohammed V for Solidarity, removing financial barriers to implementation. BlinkLab will retain ownership of the data generated through the program, which is expected to provide valuable real-world insights into largescale screening applications. The initiative also aligns with internationally recognised healthcare standards, supporting equitable access to early diagnosis across regions. In addition, the program will include the development of a dedicated Center of Excellence for Autism Research, Education and Training, with participation from BlinkLab leadership. This deployment represents a major step in validating BlinkLab’s technology at scale, while positioning the company for potential future regulatory and commercial expansion.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au